Your browser doesn't support javascript.
loading
Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Russell, Richard J; Chachi, Latifa; FitzGerald, J Mark; Backer, Vibeke; Olivenstein, Ronald; Titlestad, Ingrid L; Ulrik, Charlotte Suppli; Harrison, Timothy; Singh, Dave; Chaudhuri, Rekha; Leaker, Brian; McGarvey, Lorcan; Siddiqui, Salman; Wang, Millie; Braddock, Martin; Nordenmark, Lars H; Cohen, David; Parikh, Himanshu; Colice, Gene; Brightling, Christopher E.
Afiliación
  • Russell RJ; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.
  • Chachi L; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.
  • FitzGerald JM; Institute for Heart and Lung Health, University of British Columbia, Vancouver, BC, Canada.
  • Backer V; Department of Respiratory Medicine, Bispebjerg Hospital, Copenhagen University, Copenhagen, Denmark.
  • Olivenstein R; Respiratory Division, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.
  • Titlestad IL; Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark.
  • Ulrik CS; Department of Respiratory Medicine, Hvidovre University Hospital, Hvidovre, Denmark.
  • Harrison T; NIHR Respiratory Biomedical Research Centre, University of Nottingham, Nottingham, UK.
  • Singh D; Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.
  • Chaudhuri R; Respiratory Medicine Department, Gartnavel General Hospital, Glasgow, UK; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
  • Leaker B; Respiratory Clinical Trials, Queen Anne Street Medical Centre, London, UK.
  • McGarvey L; Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK.
  • Siddiqui S; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.
  • Wang M; Respiratory Global Medicines Development, AstraZeneca, Cambridge, UK.
  • Braddock M; Respiratory Global Medicines Development, AstraZeneca, Cambridge, UK.
  • Nordenmark LH; Respiratory Global Medicines Development, AstraZeneca, Gothenburg, Sweden.
  • Cohen D; Respiratory Global Medicines Development, AstraZeneca, Gaithersburg, MD, USA.
  • Parikh H; Respiratory Global Medicines Development, AstraZeneca, Mississauga, ON, Canada.
  • Colice G; Respiratory Global Medicines Development, AstraZeneca, Gaithersburg, MD, USA.
  • Brightling CE; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK. Electronic address: ceb17@le.ac.uk.
Lancet Respir Med ; 6(7): 499-510, 2018 07.
Article en En | MEDLINE | ID: mdl-29793857
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma / Inflamación / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte / Europa Idioma: En Revista: Lancet Respir Med Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma / Inflamación / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte / Europa Idioma: En Revista: Lancet Respir Med Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido